Table:
|  |  | Fiscal Year Ended August 31, |  |
| --- | --- | --- | --- |
|  | 2019 | 2018 | 2017 |
| Intrinsic value of SARS exercised | $335 | $909 | $5,053 |
| Fair value of restricted stock units vested | $49,725 | $62,592 | $44,010 |
| Tax benefit for stock compensation expense(1) | $611 | $1,122 | $560 |
| Unrecognized stock-based compensation expense — restricted stock units | $41,778 |  |  |
| Remaining weighted-average period for restricted stock units expense | 1.3years |  |  |
Paragraphs:
The following table represents the restricted stock units and SARS stock-based compensation information for the periods indicated (in thousands):
(1) Classified as income tax expense within the Consolidated Statements of Operations.
Question:
What was the change in the Intrinsic value of SARS exercised between 2017 and 2018?